[{"id":"ed7b8404-0f3f-4d03-b259-8cbdfacd2292","acronym":"KEYNOTE-F62","url":"https://clinicaltrials.gov/study/NCT06108050","created_at":"2023-10-30T16:13:05.018Z","updated_at":"2025-02-25T16:19:13.834Z","phase":"Phase 1","brief_title":"JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT06108050 - KEYNOTE-F62","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • JZP898"],"overall_status":"Recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-05"},{"id":"5037edde-68fc-4ba2-be19-0dd9cdd215d1","acronym":"INFINITE","url":"https://clinicaltrials.gov/study/NCT03710876","created_at":"2025-02-26T07:43:54.912Z","updated_at":"2025-02-26T07:43:54.912Z","phase":"Phase 3","brief_title":"Efficacy \u0026 Safety of RAd-IFN Administered with Celecoxib \u0026 Gemcitabine in Patients with Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT03710876 - INFINITE","lead_sponsor":"Ferring Ventures Limited","biomarkers":" MSLN • EFEMP1","pipe":"","alterations":" ","tags":["MSLN • EFEMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-11-08"},{"id":"1f17b25f-68c6-4567-8949-45ac3df1083a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04157517","created_at":"2021-01-18T20:16:52.449Z","updated_at":"2024-07-02T16:35:26.289Z","phase":"Phase 1/2","brief_title":"A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04157517","lead_sponsor":"Takeda","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • modakafusp alfa (TAK-573)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 11/04/2023","primary_completion_date":" 11/04/2023","study_txt":" Completion: 11/04/2023","study_completion_date":" 11/04/2023","last_update_posted":"2023-12-14"},{"id":"d886936b-36f5-4752-8f4f-80f034f5322b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574730","created_at":"2021-01-18T02:05:56.207Z","updated_at":"2025-02-25T15:57:28.177Z","phase":"","brief_title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00574730","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/23/2001","start_date":" 05/23/2001","primary_txt":" Primary completion: 08/01/2005","primary_completion_date":" 08/01/2005","study_txt":" Completion: 06/07/2012","study_completion_date":" 06/07/2012","last_update_posted":"2023-09-14"},{"id":"d159abba-1cb8-4c4b-979c-655d4360cdeb","acronym":"IPOS","url":"https://clinicaltrials.gov/study/NCT04798612","created_at":"2021-03-15T15:53:50.557Z","updated_at":"2024-07-02T16:35:39.694Z","phase":"Phase 2","brief_title":"Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression","source_id_and_acronym":"NCT04798612 - IPOS","lead_sponsor":"Zealand University Hospital","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-17"},{"id":"24653085-881e-4903-a522-c30baa886f8e","acronym":"TEM-GBM","url":"https://clinicaltrials.gov/study/NCT03866109","created_at":"2021-07-05T17:20:43.739Z","updated_at":"2024-07-02T16:35:57.223Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Temferon in Patients With Glioblastoma \u0026 Unmethylated MGMT","source_id_and_acronym":"NCT03866109 - TEM-GBM","lead_sponsor":"Genenta Science","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-01-20"},{"id":"aea14076-21d7-468d-aaaf-017ccde487e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000754","created_at":"2021-01-29T06:52:32.200Z","updated_at":"2025-02-25T13:06:57.647Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3","source_id_and_acronym":"NCT00000754","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 02/01/1995","study_completion_date":" 02/01/1995","last_update_posted":"2021-11-04"},{"id":"28e36f19-bd78-45d2-b015-7dbcf89dc3a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000764","created_at":"2021-01-29T06:52:33.349Z","updated_at":"2024-07-02T16:36:22.294Z","phase":"Phase 1","brief_title":"Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.","source_id_and_acronym":"NCT00000764","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 07/01/1996","study_completion_date":" 07/01/1996","last_update_posted":"2021-10-28"},{"id":"c24ceb5a-a63d-4f4b-a68e-78ae3a0662b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02328755","created_at":"2021-06-22T23:53:57.959Z","updated_at":"2024-07-02T16:36:23.422Z","phase":"Phase 1/2","brief_title":"Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia","source_id_and_acronym":"NCT02328755","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 03/25/2019","primary_completion_date":" 03/25/2019","study_txt":" Completion: 03/25/2019","study_completion_date":" 03/25/2019","last_update_posted":"2021-10-06"},{"id":"168e1448-cbe1-4429-b2af-501da661483e","acronym":"MSIT","url":"https://clinicaltrials.gov/study/NCT02381379","created_at":"2021-01-18T11:20:49.268Z","updated_at":"2024-07-02T16:36:41.055Z","phase":"Phase 3","brief_title":"Malaysia Stop Tyrosine Kinase Inhibitor Trial","source_id_and_acronym":"NCT02381379 - MSIT","lead_sponsor":"Ministry of Health, Malaysia","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Unknown status","enrollment":" Enrollment 118","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2020-09-14"},{"id":"4ac01f41-47c9-424d-8c92-8d8f714655fc","acronym":"SPIRIT","url":"https://clinicaltrials.gov/study/NCT00219739","created_at":"2022-04-24T08:54:17.322Z","updated_at":"2025-02-25T15:47:30.851Z","phase":"Phase 3","brief_title":"STI571 ProspectIve RandomIzed Trial: SPIRIT","source_id_and_acronym":"NCT00219739 - SPIRIT","lead_sponsor":"Poitiers University Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 789","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2020-04-13"},{"id":"c2127c94-b5aa-4264-be7a-ee93fa6a03a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259856","created_at":"2021-01-18T05:04:56.061Z","updated_at":"2024-07-02T16:37:00.069Z","phase":"Phase 3","brief_title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259856","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2019-04-30"},{"id":"3629edc5-f527-4087-a4f7-97f634c0b8f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01544920","created_at":"2022-07-18T07:54:24.897Z","updated_at":"2024-07-02T16:37:07.027Z","phase":"Phase 3","brief_title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","source_id_and_acronym":"NCT01544920","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" IFNL3","pipe":"","alterations":" ","tags":["IFNL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 737","initiation":"Initiation: 05/30/2012","start_date":" 05/30/2012","primary_txt":" Primary completion: 05/19/2015","primary_completion_date":" 05/19/2015","study_txt":" Completion: 05/19/2015","study_completion_date":" 05/19/2015","last_update_posted":"2018-09-11"},{"id":"c348c65a-870f-40cf-88ec-7ac6203600f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00678951","created_at":"2021-01-18T02:32:16.777Z","updated_at":"2024-07-02T16:37:16.654Z","phase":"Phase 2","brief_title":"Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults","source_id_and_acronym":"NCT00678951","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-11-06"},{"id":"f2e641f4-5aa8-4988-8818-2ec0a4718aa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00396019","created_at":"2021-01-18T01:23:00.917Z","updated_at":"2024-07-02T16:37:16.587Z","phase":"Phase 2","brief_title":"Study of PEG-Intron for Plexiform Neurofibromas","source_id_and_acronym":"NCT00396019","lead_sponsor":"University of Pittsburgh","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2017-11-06"},{"id":"8b8fa052-0810-47f2-9451-706b3f201858","acronym":"","url":"https://clinicaltrials.gov/study/NCT01687244","created_at":"2021-01-18T07:19:07.786Z","updated_at":"2024-07-02T16:37:19.647Z","phase":"Phase 2","brief_title":"Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer","source_id_and_acronym":"NCT01687244","lead_sponsor":"FKD Therapies Oy","biomarkers":" IFNA1","pipe":" | ","alterations":" IFNA2 elevation","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNA2 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adstiladrin (nadofaragene firadenovec-vncg)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-07-24"},{"id":"b94011db-053b-47ae-9c01-264107c289cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496807","created_at":"2021-01-18T06:16:24.075Z","updated_at":"2025-02-25T16:02:11.159Z","phase":"Phase 1","brief_title":"Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma","source_id_and_acronym":"NCT01496807","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/17/2012","start_date":" 02/17/2012","primary_txt":" Primary completion: 03/16/2016","primary_completion_date":" 03/16/2016","study_txt":" Completion: 08/29/2016","study_completion_date":" 08/29/2016","last_update_posted":"2017-04-28"},{"id":"bae963e4-cf50-4606-a61b-3d77d2ae9a7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00759109","created_at":"2021-01-18T02:52:04.305Z","updated_at":"2024-07-02T16:37:23.658Z","phase":"Phase 3","brief_title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","source_id_and_acronym":"NCT00759109","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" AFP • PCNA","pipe":"","alterations":" ","tags":["AFP • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":" Completion: 11/01/2009","study_completion_date":" 11/01/2009","last_update_posted":"2017-04-07"},{"id":"2cfb63f8-caef-4e92-b1d4-4723a0502155","acronym":"","url":"https://clinicaltrials.gov/study/NCT01463956","created_at":"2021-10-27T14:53:03.432Z","updated_at":"2025-02-25T16:02:01.047Z","phase":"Phase 2","brief_title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","source_id_and_acronym":"NCT01463956","lead_sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","biomarkers":" IFNL3 • ITPA","pipe":"","alterations":" ","tags":["IFNL3 • ITPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 01/06/2012","start_date":" 01/06/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 01/22/2015","study_completion_date":" 01/22/2015","last_update_posted":"2017-01-24"},{"id":"4debac25-5f39-463e-8915-abc74602ad24","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259817","created_at":"2021-01-18T05:04:55.274Z","updated_at":"2024-07-02T16:37:26.611Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259817","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-11"},{"id":"00c80baa-e936-4958-a5aa-2b8e676204c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01838772","created_at":"2021-01-18T08:11:20.456Z","updated_at":"2024-07-02T16:37:28.161Z","phase":"Phase 4","brief_title":"HCV Treatment in HIV Co-Infected Patients in Asia","source_id_and_acronym":"NCT01838772","lead_sponsor":"amfAR, The Foundation for AIDS Research","biomarkers":" AFP • CD4","pipe":"","alterations":" ","tags":["AFP • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 188","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2016-10-27"},{"id":"7b9fa6ec-f256-4260-a160-7871d909739f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02736721","created_at":"2021-01-18T13:24:13.722Z","updated_at":"2024-07-02T16:37:29.004Z","phase":"Phase 3","brief_title":"Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)","source_id_and_acronym":"NCT02736721","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2016-09-20"},{"id":"99af91f7-a186-47e0-a42f-ee5ddd39007a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00050531","created_at":"2021-01-18T00:05:24.448Z","updated_at":"2025-02-25T15:47:04.247Z","phase":"Phase 3","brief_title":"High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)","source_id_and_acronym":"NCT00050531","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Leukine (sargramostim) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 04/01/2007","primary_completion_date":" 04/01/2007","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2016-05-11"}]